This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Miron B , Hoffman-Censits JH , Anari F , O'Neill J , Geynisman DM , Zibelman MR , Kutikov A , Viterbo R , Greenberg RE , Chen D , Lallas CD , Trabulsi EJ , Alpaugh RK , Dulaimi E , Golemis EA , Uzzo R , Ross EA , Plimack ER
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Eur Urol Oncol. 2020 Aug;3(4) :544-547
PMID: 32165095 PMCID: PMC7689684 URL: https://www.ncbi.nlm.nih.gov/pubmed/32165095
AbstractCisplatin-based neoadjuvant chemotherapy (NAC) has demonstrated an overall survival (OS) benefit in muscle-invasive bladder cancer (MIBC). However, only a subset of patients (25-50%) have a pathologic complete response at cystectomy. Using a cohort of 58 patients from two phase 2 trials, our group previously reported that mutations in the ATM, RB1, and FANCC genes correlate with complete response to cisplatin-based NAC, and consequently improve OS and disease-specific survival (DSS). These trials enrolled patients with T2-4 (N0 or N1) MIBC and treated them with accelerated/dose-dense NAC with methotrexate, vinblastine, adriamycin, and cisplatin, or gemcitabine and cisplatin, with a plan for curative cystectomy. Updated long-term follow-up (median 74 mo) shows that significantly greater OS and DSS was maintained for patients with ATM, RB1, or FANCC mutations. The 5-yr survival rate for patients with at least one mutation was 85%, compared to 45% for patients without a mutation. On the basis of the associations with response and long-term OS and DSS, we propose that these alterations may be useful as predictive biomarkers to allow clinicians to prioritize patients who are most likely to benefit from NAC before radical cystectomy. PATIENT SUMMARY: In this report we looked at outcomes for patients with muscle-invasive bladder cancer treated with cisplatin-based chemotherapy before surgery (neoadjuvant) who had mutations in a set of DNA damage repair genes (ATM, RB1, FANCC) compared to those who did not. We found that patients who had at least one mutation in one of these genes survived longer after receiving cisplatin chemotherapy before surgery than patients who did not.
Notes2588-9311 Miron, Benjamin Hoffman-Censits, Jean H Anari, Fern O'Neill, John Geynisman, Daniel M Zibelman, Matthew R Kutikov, Alexander Viterbo, Rosalia Greenberg, Richard E Chen, David Lallas, Costas D Trabulsi, Edouard J Alpaugh, R Katherine Dulaimi, Essel Golemis, Erica A Uzzo, Robert Ross, Eric A Plimack, Elizabeth R Journal Article Netherlands Eur Urol Oncol. 2020 Mar 10. pii: S2588-9311(20)30028-6. doi: 10.1016/j.euo.2020.02.003.